Literature DB >> 26296373

Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Abdulmaged M Traish1, Roberto Cosimo Melcangi2, Marco Bortolato3, Luis M Garcia-Segura4, Michael Zitzmann5.   

Abstract

Steroids are important physiological orchestrators of endocrine as well as peripheral and central nervous system functions. One of the key processes for regulation of these molecules lies in their enzymatic processing by a family of 5α-reductase (5α-Rs) isozymes. By catalyzing a key rate-limiting step in steroidogenesis, this family of enzymes exerts a crucial role not only in the physiological control but also in pathological events. Indeed, both 5α-R inhibition and supplementation of 5α-reduced metabolites are currently used or have been proposed as therapeutic strategies for a wide array of pathological conditions. In particular, the potent 5α-R inhibitors finasteride and dutasteride are used in the treatments of benign prostatic hyperplasia (BPH), as well as in male pattern hair loss (MPHL) known as androgenetic alopecia (AGA). Recent preclinical and clinical findings indicate that 5α-R inhibitors evoke not only beneficial, but also adverse effects. Future studies should investigate the biochemical and physiological mechanisms that underlie the persistence of the adverse sexual side effects to determine why a subset of patients is afflicted with such persistence or irreversible adverse effects. Also a better focus of clinical research is urgently needed to better define those subjects who are likely to be adversely affected by such agents. Furthermore, research on the non-sexual adverse effects such as diabetes, psychosis, depression, and cognitive function are needed to better understand the broad spectrum of the effects these drugs may elicit during their use in treatment of AGA or BPH. In this review, we will summarize the state of art on this topic, overview the key unresolved questions that have emerged on the pharmacological targeting of these enzymes and their products, and highlight the need for further studies to ascertain the severity and duration of the adverse effects of 5α-R inhibitors, as well as their biological underpinnings.

Entities:  

Keywords:  5α-Reductases; Adverse effects; Benign prostate hyperplasia; Dutasteride; Finasteride; Neurosteroids; Sexual dysfunction

Mesh:

Substances:

Year:  2015        PMID: 26296373     DOI: 10.1007/s11154-015-9319-y

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  204 in total

Review 1.  Neurogenic pain and steroid synthesis in the spinal cord.

Authors:  Christine Patte-Mensah; Cherkaouia Kibaly; Domitille Boudard; Véronique Schaeffer; Aurélie Béglé; Simona Saredi; Laurence Meyer; Ayikoe G Mensah-Nyagan
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  The enantiomer of progesterone acts as a molecular neuroprotectant after traumatic brain injury.

Authors:  Jacob W VanLandingham; Sarah M Cutler; Sharad Virmani; Stuart W Hoffman; Douglas F Covey; Kathiresan Krishnan; Stephen R Hammes; Michelle Jamnongjit; Donald G Stein
Journal:  Neuropharmacology       Date:  2006-08-22       Impact factor: 5.250

Review 3.  Neuroactive steroids: state of the art and new perspectives.

Authors:  R C Melcangi; L M Garcia-Segura; A G Mensah-Nyagan
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

Review 4.  Allopregnanolone: state of the art.

Authors:  Roberto Cosimo Melcangi; Gian Carlo Panzica
Journal:  Prog Neurobiol       Date:  2013-10-10       Impact factor: 11.685

5.  Renal capture and oxidation of cortisol in man.

Authors:  L Hellman; F Nakada; B Zumoff; D Fukushima; H L Bradlow; T F Gallagher
Journal:  J Clin Endocrinol Metab       Date:  1971-07       Impact factor: 5.958

6.  Persistent sexual side effects of finasteride for male pattern hair loss.

Authors:  Michael S Irwig; Swapna Kolukula
Journal:  J Sex Med       Date:  2011-03-18       Impact factor: 3.802

7.  Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes.

Authors:  L D Griffin; S H Mellon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

8.  Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension.

Authors:  B R Walker; P M Stewart; C H Shackleton; P L Padfield; C R Edwards
Journal:  Clin Endocrinol (Oxf)       Date:  1993-08       Impact factor: 3.478

Review 9.  Androgen metabolism in adipose tissue: recent advances.

Authors:  Karine Blouin; Alain Veilleux; Van Luu-The; André Tchernof
Journal:  Mol Cell Endocrinol       Date:  2008-11-05       Impact factor: 4.102

10.  Therapeutic effects of progesterone and its metabolites in traumatic brain injury may involve non-classical signaling mechanisms.

Authors:  Paul S Cooke; Manjunatha K Nanjappa; Zhihui Yang; Kevin K W Wang
Journal:  Front Neurosci       Date:  2013-06-13       Impact factor: 4.677

View more
  27 in total

1.  Allopregnanolone is required for prepulse inhibition deficits induced by D1 dopamine receptor activation.

Authors:  Laura J Mosher; Roberto Cadeddu; Sabrina Yen; Jeffrey L Staudinger; Francesco Traccis; Stephen C Fowler; Jamie L Maguire; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2019-06-14       Impact factor: 4.905

Review 2.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

Review 3.  Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?

Authors:  Silvia Giatti; Silvia Diviccaro; Giancarlo Panzica; Roberto Cosimo Melcangi
Journal:  Endocrine       Date:  2018-04-19       Impact factor: 3.633

Review 4.  The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.

Authors:  Mohammed A Said; Akanksha Mehta
Journal:  Curr Urol Rep       Date:  2018-06-16       Impact factor: 3.092

Review 5.  Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

Authors:  Jason M Hirshburg; Petra A Kelsey; Chelsea A Therrien; A Carlo Gavino; Jason S Reichenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

6.  Balancing tonic and phasic inhibition in hypothalamic corticotropin-releasing hormone neurons.

Authors:  Phillip L W Colmers; Jaideep S Bains
Journal:  J Physiol       Date:  2018-03-14       Impact factor: 5.182

7.  Macular Abnormalities Associated With 5α-Reductase Inhibitor.

Authors:  Yong Kyun Shin; Geun Woo Lee; Se Woong Kang; Sang Jin Kim; A Young Kim
Journal:  JAMA Ophthalmol       Date:  2020-07-01       Impact factor: 7.389

8.  The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder.

Authors:  Gabriel D Bosse; Roberto Cadeddu; Gabriele Floris; Ryan D Farero; Eva Vigato; Suhjung J Lee; Tejia Zhang; Nilesh W Gaikwad; Kristen A Keefe; Paul Em Phillips; Marco Bortolato; Randall T Peterson
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

9.  Androgen receptors in areas of the spinal cord and brainstem: A study in adult male cats.

Authors:  Rosa L Coolen; Jacqueline C Cambier; Panagiota I Spantidea; Els van Asselt; Bertil F M Blok
Journal:  J Anat       Date:  2021-02-22       Impact factor: 2.610

10.  Alterations of gut microbiota composition in post-finasteride patients: a pilot study.

Authors:  F Borgo; A D Macandog; S Diviccaro; E Falvo; S Giatti; G Cavaletti; R C Melcangi
Journal:  J Endocrinol Invest       Date:  2020-09-19       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.